Rain Therapeutics Inc. (RAIN) Social Stream
RAIN ONCOLOGY INC (RAIN) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering RAIN ONCOLOGY INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-10 | 3 | $28 | $25 | $26.333 | $1.2 | 2094.42% |
| 2022-03-03 | 4 | $28 | $26 | $26.666 | $1.2 | 2122.17% |
| 2022-05-04 | 4 | $28 | $15 | $23.75 | $1.2 | 1879.17% |
| 2022-05-05 | 2 | $26 | $16 | $21 | $1.2 | 1650% |
| 2022-05-27 | 2 | $16 | $12 | $14 | $1.2 | 1066.67% |
| 2022-08-05 | 3 | $16 | $12 | $14.666 | $1.2 | 1122.17% |
| 2022-11-11 | 4 | $16 | $10 | $13.5 | $1.2 | 1025% |
| 2022-11-23 | 5 | $29 | $12 | $17 | $1.2 | 1316.67% |
| 2023-01-05 | 7 | $29 | $12 | $16.833 | $1.2 | 1302.75% |
| 2023-01-06 | 6 | $29 | $12 | $17 | $1.2 | 1316.67% |
| 2023-01-20 | 6 | $29 | $12 | $17.5 | $1.2 | 1358.33% |
| 2023-01-23 | 7 | $29 | $12 | $17.571 | $1.2 | 1364.25% |
| 2023-03-10 | 8 | $29 | $12 | $18 | $1.2 | 1400% |
| 2023-03-13 | 8 | $29 | $15 | $18.75 | $1.2 | 1462.5% |
| 2023-05-15 | 9 | $24 | $11 | $17.333 | $1.2 | 1344.42% |
| 2023-05-23 | 10 | $17 | $1.5 | $6.607 | $1.2 | 450.58% |
| 2023-05-30 | 10 | $17 | $1.5 | $6.607 | $1.2 | 450.58% |
| 2023-05-31 | 10 | $17 | $1.2 | $6.064 | $1.2 | 405.33% |
| 2023-08-10 | 9 | $17 | $1 | $4.208 | $1.2 | 250.67% |
| 2023-09-18 | 6 | $1.75 | $1 | $1.25 | $1.2 | 4.17% |
| 2023-11-09 | 9 | $17 | $1 | $4.125 | $1.2 | 243.75% |
| 2023-12-14 | 7 | $1.75 | $1 | $1.227 | $1.2 | 2.25% |
The Trend in the Analyst Price Target
RAIN's average price target has moved down $24.02 over the prior 27 months.
Over the past 47 weeks, RAIN's average upside potential has been 235.54%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-23 | 8 | 29 | 12.0 | 17.571 | 9.85 | 78.39% |
| 2023-01-23 | 7 | 29 | 12.0 | 17.500 | 9.85 | 77.66% |
| 2023-02-09 | 8 | 29 | 12.0 | 18.000 | 9.00 | 100% |
| 2023-03-31 | 9 | 24 | 11.0 | 17.333 | 8.74 | 98.32% |
| 2023-05-23 | 9 | 17 | 1.5 | 6.607 | 1.24 | 432.82% |
RAIN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 7 | 0 | 0 | 7 |
The Trend in the Broker Recommendations
RAIN's average broker recommendation rating worsened by 1.33 over the prior 30 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RAIN as an investment opportunity.
- In terms of how RAIN ONCOLOGY INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 3246.84% of that group.
- In the context of all US stocks, RAIN ONCOLOGY INC's variance in analysts' estimates is lower than -2367.43% of them.
- To contextualize these metrics, consider that out of stocks in the small market cap category, RAIN ONCOLOGY INC's number of analysts covering the stock is greater than 2333.48% of them.
- RAIN ONCOLOGY INC's average analyst price target is higher than 884.46% of Healthcare stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to RAIN ONCOLOGY INC are VERA, DAWN, and CNTA.
View All Top Stocks by Price Target
Is RAIN a Buy, Hold or Sell? See the POWR Ratings now!